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ABSTRAK
Tujuan: mengetahui karakteristik fenotip bakteri Gram negatif famili Enterobacteriaceae penghasil enzim 
beta-laktamase, seperti ESBL, AmpC, dan karbapenemase. Metode: tiga metode berbeda dilakukan untuk 
mengkonfirmasi karakteristik fenotip ketiga enzim tersebut, yaitu metode difusi cakram untuk konfirmasi ESBL, 
uji cakram AmpC (berbasis cefoxitin) untuk konfirmasi AmpC, dan uji Hodge termodifikasi untuk konfirmasi 
karbapenemase. Hasil: dengan metode difusi cakram ganda, kami dapatkan 58.42% isolat merupakan penghasil 
ESBL, 1.98% merupakan penghasil AmpC dengan uji cakram AmpC (berbasis cefoxitin), dan 27.59% merupakan 
penghasil karbapenemase dengan uji Hodge termodifikasi. Kesimpulan: hasil penelitian ini menunjukkan 
prevalensi Klebsiella pneumoniae penghasil beta-laktamase khususnya ESBL sangat tinggi, dan tentu saja AmpC 
dan karbapenemase tidak boleh diabaikan sebagai penyebab infeksi meskipun presentasenya kecil.
Kata kunci: Enterobacteriaceae, resistensi antibiotik, ESBL, AmpC, karbapenemase.
ABSTRACT
Aim: the goal of this study is to understand the phenotype characteristic of beta-lactamase enzymes 
producing Enterobacteriaceae, such as ESBL, AmpC, and carbapenemase. Methods: three different methods 
are performed to confirm those phenotypic characteristics, namely double disk diffusion method to confirm 
ESBL, AmpC disk test (cefoxitin-based) to confirm AmpC, and modified Hodge test to confirm carbapenemase. 
Results: using double disk diffusion method, we found 58.42% isolates are ESBL-producing, whereas the outcomes 
of AmpC disk test shows 1.98% are AmpC-producing. By conducting modified Hodge test (MHT), 27.59% isolates 
are confirmed as carbapenemase-producing bacteria. Conclusion: this study confirmed the prevalence of beta-
lactamase producing Klebsiella pneumoniae is very high. Nevertheless, AmpC and carbapenemase should not 
be ignored despite their low prevalence.
Key words: Enterobacteriaceae, antibiotic resistance, ESBL, AmpC, carbapenemase.
INTRODUCTION
The increasing incidence of antibiotics 
resistance is getting more global attention. The 
absence of antibiotic regulation in most Asian 
countries, including Indonesia, is believed to have 
contribution to the rapidly increasing infections of 
multi-resistance pathogenic bacterias.1 Infectious 
disease experts and clinical microbiologists 
have agreed that antibiotic multi-resistant Gram 
negative bacterias pose the greatest risk to the 
public health. This happens not only because of 
the resistance of Gram negative bacteria is faster 
than those of Gram positive, but also the discovery 
and development of new antibiotics to fight Gram 
negative bacteria are far fewer.2 Many references 
reported that the increasing resistancies of Gram 
negative is due to mobile genetic elements, thus 
readily spread through bacterial population.2,3
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A m o n g  G r a m  n e g a t i v e  b a c t e r i a , 
Enterobacteriaceae is the most common cause of 
hospital acquired infections, such as urinary tract 
infection, blood stream infection, pneumonia, and 
abdominal infection.4 High number of antibiotic 
resistance of those bacterias have been reported 
in many countries. This should be taken into 
consideration when choosing proper antibiotics, 
especially to patients with severe or critical 
illness and those who need immediate therapy, 
for example, intensive care unit (ICU) patients. 
Enterobacteriaceae resistant to third 
generation cephalosporin are tipically caused 
by production of beta-lactamase enzyme, known 
as extended-spectrum beta lactamase (ESBL) 
[Ambler class A]. The genes that encode are 
frequently found on the same plasmid as genes 
that encode resistance to aminoglycoside, 
sulfonamide, and quinolons. These indicate that 
ESBL producing Enterobacteriaceae in hospitals, 
especially ICUs, are multidrug resistant.4 Inproper 
empiric antibiotic to treat nosocomial infection 
contribute significantly to high mortality rate in 
ICUs.1,4 In addition to ESBL, resistant to third 
generation cephalosporin may also be caused 
by the production of AmpC cephamycinase 
enzyme (AmpC) [Ambler class C] especially by 
Enterobacter spp and Citrobacter spp, and encoded 
by AmpC genes in the cromosom. However, the 
the AmpC encoding genes may also be mediated 
by plasmid [Ambler class D].6 The AmpC 
producing bacteria is resistant to cephamycin 
(cefoxitin) too.6 Carbapenem, like imipenem and 
meropenem, is the first line therapy recommended 
for severe infection due to ESBL producing 
Enterobacteriaceae.7 In spite of this, since 2000, 
resistance to carbapenem antibiotics have also 
been reported.8 Most common carbapenemase in 
Enterobacteriaceae is K. pneumoniae producing 
carbapenemase (KPC), especially in US, Asia, 
England, Israel, and Southern Europe.7 In 2009, 
new type of carbapenemase called New Delhi 
Metalo-β-lactamase 1 (NDM-1) was reported 
[Ambler class B].2,8,9 These findings are worrying 
because the choice in antibiotic therapy is getting 
more limited.
Taking a l l  informat ion above into 
consideration, antibiotic susceptibility test 
alone is not enough. Confirmation of phenotype 
characteristic of these beta–lactamase enzymes is 
important to be done, not only for epidemiology 
matters, also for patient’s safety. 
This study is a collaboration project of 
Clinical Microbiology Laboratory Faculty of 
Medicine University of Indonesia (CML-FMUI) 
and Intensive Care Unit, Cipto Mangunkusumo 
Hospital (ICU RSCM). We expect to obtain 
preliminary data on the prevalence of each 
phenotypic character with the intention that it 
could be the useful guidance to treat patients 
with antibiotics. The final outcomes would 
be reduction of hospital stay and treatment 
cost, better infection control in hospitals, and 
prevention of resistance spreading.
METHODS
Study Design
This study is a retrospective study with 
subjects consisting of all ICU patients of Cipto 
Mangunkusumo Hospital (RSCM) hospitalized 
during January to December 2011. All samples are 
taken based on CML-FMUI standard operational 
procedure.
Sample Size
By taking alpha (α) value 0.05, then Zα 
is 1.96 (normal curve), p is proportion of 
patient with Enterobacteriaceae producing beta 
lactamase infection, while q is proportion of 
patient with no Enterobacteriaceae producing 
beta lactamase infection. Based on SENTRY 
Asia-Pacific Surveillance Program that was 
conducted in 1998–2002, ESBL prevalence 
has reached 60% in several Asian countries,1 p 
value 60% and q value (100%-60% = 40%), with 
allowable error (L) was 10%, the sample size 
needed is 103 isolates.
Patient samples were routinely collected 
for clinical purposes and then reanalyzed 
for the purposes of this study. During the 
1-year period, from January until December 
2011, all hospitalized patients at ICU Cipto 
Mangunkusumo Hospital were included.
Bacterial Isolates 
Samples are clinical isolates from ICU 
patients of Cipto Mangunkusumo Hospital in 
2011 which have been reserved as biological 
material in Laboratory of Clinical Microbiology, 
Faculty of Medicine. All isolates has been 
identified as Enterobacteriaceae using API 
20E system (BioMerieux®). Those isolates 
have passed susceptibility test that resistant to 
one or more antibiotic from third generation 
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cephalosporin and/or resistant to aztreonam 
and/or intermediate or resistant to one or more 
antibiotic from carbapenem class.
Phenotypic Confirmation
Three different methods are performed to 
confirm phenotypic characteristics i.e.: (1). 
Double disk diffusion method to confirm the 
production of ESBL, (2). AmpC disk test to 
confirm the production of AmpC, and (3). 
Modified Hodge test (MHT) to confirm the 
production of carbapenemase.
This study has passed evaluation at the 
Faculty of Medicine University of Indonesia/
Cipto Mangunkusumo Hospital Ethics Committee 
(Letter no. 318/PT02.FK/ETIK/2012).
RESULTS
Based on ICU patients’ record we found 84 
patients with microbiology examination results 
showed infection of Enterobacteriaceae family 
bacteria. Those patients consist of 56% male and 
44% female, with age ranging from 1 to 86 years. 
The percentage of medical and surgical cases are 
similar (50%:50%).
The total numbers of isolates from those 
84 patients are 112 because several patients 
had more than one examination. Sputum is the 
primary source of isolates with almost 60%, the 
rest are from 12 other sources i.e. urine, pus, 
blood, etc. (Table 1).
Not all isolates proceeded to the phenotypic 
confirmation test. Referring to CML-FMUI 
WHONET susceptibility data, 11 of 112 isolates 
(9.82%) are still sensitive to third generation 
cephalosporin, aztreonam, and carbapenem. 
Among 101 isolates (90.18%) that are resistant 
to third generation cephalosporin and aztreonam, 
29 isolates (25.89%) are found to be resistant to 
carbapenemase too. Phenotypic confirmation test 
for ESBL and AmpC were conducted on those 
101 isolates, while 29 of them were also tested 
for carbapenemase.
Later after conducting double disk diffusion 
and AmpC disk test to those second category 
isolates above, we confirm 58.42% are ESBL 
positive and 1.98% are AmpC positive. 
Meanwhile, modified Hodge test conducted to 
29 isolates included to the third category, 27.59% 
are carbapenemase positive but not with strong 
indication (weak positive).
Among ESBL positive patients, 78% were 
clinically improving and 22% patients has died, 
while the percentage among ESBL negative 
patients are 83% and 17%, respectively.
Then we conducted the Chi-square test 
to analyze the statistical association between 
infection of beta lactamase-producing 
Enterobactericeae with age, gender, clinical 
manifestation (medical or surgery), and outcome 
(died or clinically improving). The association 
between those variable were found to be 
statistically insignificant (p>0.05).














The 112 isolates are then further analyzed 
to identify their species and phenotypic 
characteristic. (Table 2)
Table 2. Enterobacteriaceae isolates
Enterobacteriaceae species Number of isolates (%)
Klebsiella pneumoniae 61 (54,46)
Escherichia coli 15 (13,39)
Proteus mirabilis 9 (8,04)
Serratia liquafaciens 5 (4,46)
Serratia odorifera 5 (4,46)
Enterobacter cloacae 5 (4,46)
Citrobacter freundii 3 (2,67)
Salmonella arizonae 2 (1,78)
Klebsiella oxytoca 2 (1,78)
Serratia ficaria 1 (0,9)
Serratia fonticola 1 (0,9)
Serratia marcescens 1 (0,9)
Edwardsiella tarda 1 (0,9)
Shigella A 1 (0,9)
Total 112 (100)
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DISCUSSION
The high number of ESBL-producing bacteria 
found in this study is similar with the result of 
SENTRY Asia Pacific surveillance program study 
conducted during 1998 to 2002 in which the result 
is around 60% in several Asian countries.1
The considerably low AmpC might not 
indicate the true prevalence. Some isolates that 
showed the reduction of cefoxitin inhibition zone 
could not be concluded as AmpC positive due to 
the absence of positive control. We recommend 
collaboration with other researchers who had 
done AmpC before to share their positive control. 
Other methods, like three dimensional test and 
boric acid based test, may also be carried out to 
compare the sensitivity and specificity.
Cefoxitin has been used mostly for 
susceptibility test of Gram positive bacteria. It 
is already known that AmpC is resistant not only 
to third generation cephalosporin and aztreonam, 
it is also resistant to cefoxitin and beta lactamase 
inhibitor.15 Therefore, we suggest using cefoxitin 
disk for routinely susceptibility test in Gram 
negative bacteria. This could be useful as initial 
screening of possible AmpC producing isolates. 
Meanwhile, carbapenemase-producing 
Enterobacteriaceae are found to be relatively 
high, but the detection using MHT indicates weak 
positive result. We recommend other methods 
as comparison and to increase the sensitivity. 
Several references stated that MHT offers very 
good sensitivity for KPC dan OXA enzymes, but 
not sensitive for VIM, IMP, and NDM.16 Another 
study suggests that adding ZnSO4 to MHA may 
increase the sensitivity for NDM producing 
Enterobacteriaceae.17 Lee et al. found that the use of 
MacConkey agar could improve MHT performance 
in detecting positive result compared to MHA.18 
Pasteran et al. concluded that indicator organism 
Klebsiella pneumoniae ATCC 700603 used for 
MHT is more sensitive than E. coli ATCC 25922, 
especially for KPC and metallo beta-lactamase.19
As many studies and many attempts to modify 
phenotypic confirmation tests for carbapenemase 
producing bacteria have been done so far, we 
suggest conducting further research to compare 
each test. Thus, we could adopt the best or most 
appropriate method for routine examination in 
microbiology laboratory to support infection 
control surveillance program in hospitals.
Having found sputum as the major source 
of specimens indicated that lower respiratory 
tract infections are highly frequent among ICU 
patients and often related to ventilator-associated 
pneumonia (VAP).
The statistically insignificant association 
between infections of Enterobacteriaceae 
producing ESBL with clinical manifestations 
ESBL (+) ESBL (-)
Figure 1. Double disk diffusion method to confirm the 
production of ESBL
AmpC (+) AmpC (-)
Figure 2. AmpC disk test to confirm the production of AmpC
Carbapenemase (+)
Figure 3. AmpC weak positive
Carbapenemase (+) Carbapenemase (-)
Figure 4. Modified Hodge test (MHT) to confirm the 
production of carbapenemase
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and outcomes does not necessarily mean that it 
is not clinically insignificant. The result of this 
study confirmed that anyone could be infected by 
ESBL-producing Enterobacteriaceae regardless 
their age, gender, and clinical manifestation. 
Although there is no direct effect on patient’s 
outcome, the infections are likely to prolong 
hospital stay and incur high cost.
Some published studies found that prior 
antibiotics administration to patients are strongly 
correlated with ESBL incidences.20-22 However, 
such an aspect was not observed in this study. We 
would conduct further research to examine the 
connection between antibiotics prescription and 
other factors with infection of beta lactamase-
producing bacteria.
CONCLUSION
This study confirmed the prevalence of beta- 
lactamase producing Klebsiella pneumoniae to be 
very high. Nevertheless, AmpC and carbapenemase 
should not be ignored despite their low prevalence. 
By understanding the resistance pattern and 
prevalence of the beta lactamase-producing 
organisms, especially Klebsiella pneumoniae, we 
would have a better infection control as well as 
proper and rational antibiotics prescription.
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